Two Sigma Investments LP Buys 52 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Two Sigma Investments LP boosted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 3.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,773 shares of the biotechnology company’s stock after acquiring an additional 52 shares during the period. Two Sigma Investments LP’s holdings in United Therapeutics were worth $626,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in UTHR. Bleakley Financial Group LLC grew its position in shares of United Therapeutics by 58.1% during the 4th quarter. Bleakley Financial Group LLC now owns 1,059 shares of the biotechnology company’s stock worth $374,000 after buying an additional 389 shares during the period. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $25,000. Savant Capital LLC grew its position in shares of United Therapeutics by 2.7% during the 4th quarter. Savant Capital LLC now owns 10,205 shares of the biotechnology company’s stock worth $3,601,000 after buying an additional 266 shares during the period. JSF Financial LLC grew its position in shares of United Therapeutics by 4.0% during the 4th quarter. JSF Financial LLC now owns 2,996 shares of the biotechnology company’s stock worth $1,057,000 after buying an additional 114 shares during the period. Finally, Louisiana State Employees Retirement System grew its position in shares of United Therapeutics by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 12,400 shares of the biotechnology company’s stock worth $4,375,000 after buying an additional 100 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, Director Raymond Dwek sold 4,000 shares of the firm’s stock in a transaction on Monday, April 7th. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the completion of the sale, the director now directly owns 1,750 shares of the company’s stock, valued at $497,962.50. This trade represents a 69.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the firm’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,500 shares of company stock worth $16,923,950. Corporate insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Morgan Stanley raised their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 1st. JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a research report on Thursday, May 1st. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an “overweight” rating and a $405.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Finally, Wall Street Zen downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $393.00.

United Therapeutics Trading Up 1.9%

Shares of NASDAQ:UTHR opened at $325.82 on Monday. The stock’s fifty day simple moving average is $301.06 and its two-hundred day simple moving average is $333.13. United Therapeutics Co. has a 1-year low of $266.98 and a 1-year high of $417.82. The stock has a market cap of $14.70 billion, a PE ratio of 14.31, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. During the same period last year, the business earned $6.17 EPS. The business’s revenue was up 17.2% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.